EIB
European Investment Bank (EIB) provides lending, borrowing, and treasury services primarily in the European Union. The company offers project loans for the public and private sectors; loans to banks and other intermediaries; structured finance products; guarantees and securitization instruments for senior and subordinated debts; project bonds; equity and fund investment products such as infrastructure equity and debt funds, and environmental funds; and venture capital funds and security packages for funds. The company also offers microfinance; risk sharing finance for research, development, and innovation projects; finance and technical expertise for sustainable energy projects; infrastructure project advisory services; support for urban development projects; guarantees for transport infrastructure; and funding for public-private partnerships and small- and medium-sized enterprises. EIB serves the transportation, global loans, energy, industry, health, education, water, sewerage, infrastructure, services, telecommunications, agriculture, and fisheries sectors. European Investment Bank was founded in 1958 and is based in Luxembourg.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
Red Points Solutions, S.L. is a technology company based in Barcelona, Spain, specializing in protecting brands from online intellectual property infringements, including counterfeiting and digital piracy. Founded in 2011, the company offers a SaaS platform that provides comprehensive brand protection solutions. This includes monitoring digital channels such as e-commerce sites, social media, and specialized websites to safeguard trademarks, designs, and patented technologies. Additionally, Red Points has an anti-piracy solution that identifies and removes infringing media content from various platforms, including streaming websites and peer-to-peer networks. The company's services are utilized by over five hundred brands globally, enabling them to effectively combat illegal products and content online.
Innovation Ulster Limited (IUL) is a knowledge and technology venturing company wholly owned by Ulster University. Its primary focus is to support the commercial development of the university's research, facilitating the transfer of valuable inventions and knowledge to the private sector. IUL aims to foster an entrepreneurial environment within the university, encouraging both staff and students to generate new inventions and educational materials. The company seeks to enhance the commercial impact of Ulster's research while ensuring that the long-term financial returns on its investments meet or exceed spending rates, all within an acceptable risk framework. Through these efforts, IUL promotes the attractiveness of Ulster's intellectual property, ultimately contributing to societal and economic advancement.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.